Tue, Oct 21, 2014, 8:05 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Alkermes plc Message Board

  • hddeuce1955 hddeuce1955 Oct 13, 2010 12:53 PM Flag

    S&P Maintains BUY rating

    S&P MAINTAINS BUY OPINION ON SHARES OF ALKERMES INC
    (Standard & Poor's)
    FDA approves ALKS's Vivitrol, a once-monthly injection for preventing relapse in patients with opioid dependence. We see considerable market opportunity in opioid market, as leader has generated sales around $1B. We expect Vivitrol's monthly formulation and non-addictive mechanism of action to provide attractive alternative, and expect drug to be fare better than approved use for alcohol dependence. We also expect FDA to approve diabetes drug Bydureon, for which ALKS would earn 8% sales royalty, on October 22 action date. We raise our NPV-based target price by $2 to $19.

 
ALKS
43.80+0.63(+1.46%)Oct 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.